1 INTRODUCTION Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment elicits significant long-term protection against negative cardiovascular and renal outcomes in patients with type 2 diabetes (Marso Bain, et al., 2016; Marso, Daniels, et al., 2016; Perkovic et al., 2024).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ali Asmar
Escalating Tensions Between Turkey and Israel: Rhetoric, Regional Rivalry, and Strategic Competition - Global Research
In a sharp escalation of rhetoric, Turkish Foreign Minister Hakan Fidan has accused Israel of attempting to position Turkey as a “new enemy” following Iran, amid increasingly tense exchanges between officials from both countries. To read this article in the following languages, click the Translate Website button below the author’s name. Türkçe, Hebrew, 中文, Farsi, Русский, Español, Portugues, عربي, Français, Deutsch, Italiano, 日本語, 한국어, Српски. And 40 more languages.
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor Meena Asmar, Ali Asmar, Lene Simonsen, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Mette Marie Rosenkilde, Bolette Hartmann, Flemming Dela, Jens Juul Holst, Jens Bülow Diabetes Sep 2017, 66 (9) 2363-2371; DOI: 10.2337/db17-0480
Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
AbstractIn healthy subjects, we recently demonstrated that during acute administration of GLP?1, cardiac output increased significantly, whereas renal blood flow remained constant. We therefore hypothesize that GLP?1 induces vasodilation in other organs, for example, adipose tissue, skeletal muscle, and/or splanchnic tissues. Nine healthy men were examined twice in random order during a 2?hour infusion of either GLP?1 (1.5 pmol kg?1 min?1) or saline.
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
We investigated the short-term effect of adding liraglutide 1.8?mg once daily to insulin treatment on cardiovascular risk factors in patients with type 1 diabetes. In total, 100 overweight (BMI ?25?kg/m2) adult patients (age ?18?years) with type 1 diabetes and HbA1c ?8% (64?mmol/mol) were randomised to liraglutide 1.8?mg or placebo added to insulin treatment in a 24-week double-blinded, placebo-controlled trial.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ali
Contact Ali, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack